Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 108Triple Negative Breast Neoplasms 27Neoplasm Metastasis 17Sarcoma 16Neoplasms 16Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 6Brain Neoplasms 5Prostatic Neoplasms 4Urinary Bladder Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 3Liposarcoma 3Inflammatory Breast Neoplasms 3HER2-negative Breast Cancer 3Carcinoma, Transitional Cell 3Urethral Neoplasms 2Ureteral Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Recurrence 2Pancreatic Neoplasms 2Melanoma 2Lymphoma 2Lung Neoplasms 2Leiomyosarcoma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma 2Advanced Breast Cancer 2

Interventions

Ifosfamide 30Methotrexate 27Doxorubicin 25Cyclophosphamide 24Cisplatin 22Filgrastim 18Etoposide 17Gemcitabine 16Leucovorin 14Magnetic Resonance Spectroscopy 11Temozolomide 10cabozantinib 9apatinib 9Specimen Handling 9Carboplatin 9fludarabine 8X-Rays 8Nivolumab 8Neoadjuvant Therapy 8Irinotecan 8Granulocyte Colony-Stimulating Factor 8Docetaxel 8Zoledronic Acid 7Vincristine 7Sirolimus 7Radiotherapy 7Phantoms, Imaging 7Biopsy 7Topotecan 6Mesna 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Osteosarcoma × eribulin × Clear all
NCT02097238 2020-05-19

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 12 charts
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡